Lauren Harshman

17PUBLICATIONS
70CO-AUTHORS
Radiation therapyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Mar 29, 2024
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Atish D Choudhury, Lucia Kwak, Alexander Cheung

|Jun 06, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.

Renee Maria Saliby, Talal El Zarif, Ziad Bakouny

|Feb 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.

Bradley A McGregor, Wanling Xie, Elio Adib

|Aug 28, 2021
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).

Russell K Pachynski, Chihiro Morishima, Russell Szmulewitz

|Nov 12, 2020
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.

Abhishek Tripathi, Edwin Lin, Wanling Xie

|Oct 27, 2020
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).

Rana R McKay, Bradley A McGregor, Wanling Xie

Pageof 3

Frequent Collaborators

8 joint publications

Toni K Choueiri

4 joint publications

Bradley A McGregor

4 joint publications

Amin H Nassar

3 joint publications

Wanling Xie